FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1847856759> ?p ?o ?g. }

• W1847856759 endingPage "105" @default.
• W1847856759 startingPage "100" @default.
• W1847856759 abstract "No AccessJournal of Urology1 Jul 1993Serum Prostate Specific Antigen Complexed to α1-Antichymotrypsin as an Indicator of Prostate Cancer Anders christensson, Thomas Björk, Olle Nilsson, Ulrika Dahlén, Marja-Terttu Matikainen, Abraham T.K. Cockett, Per-Anders Abrahamsson, and Hans Lilja Anders christenssonAnders christensson More articles by this author , Thomas BjörkThomas Björk More articles by this author , Olle NilssonOlle Nilsson More articles by this author , Ulrika DahlénUlrika Dahlén More articles by this author , Marja-Terttu MatikainenMarja-Terttu Matikainen More articles by this author , Abraham T.K. CockettAbraham T.K. Cockett More articles by this author , Per-Anders AbrahamssonPer-Anders Abrahamsson More articles by this author , and Hans LiljaHans Lilja More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)35408-3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Prostate specific antigen (PSA) in serum has recently been shown to occur in complex with α1-antichymotrypsin and as an approximately 30kDa. noncomplexed molecular form. We characterized PSA by 3 different assays in samples from 144 patients with benign prostatic hyperplasia (BPH) and 121 with carcinoma of the prostate. One of these noncompetitive assays measured total PSA by detecting PSA complexed to serine proteinase inhibitors and the noncomplexed molecular form, a second measured only PSA in complex with al-antichymotrypsin, whereas a third detected the noncomplexed form. PSA in complex with α1-antichymotrypsin was the predominant form in all patient sera. Noncomplexed PSA constituted a minor fraction that was significantly smaller in patients with untreated prostate cancer than in those with BPH (p <0.0001). The proportion of noncomplexed PSA does not correlate to the serum concentration of PSA or that of al-antichymotrypsin. In men with a serum PSA concentration of less than 10μg./l. the combination of assays measuring total PSA immunoreactivity, the noncomplexed molecular form and PSA in complex with α1-antichymotrypsin may facilitate discrimination between prostate cancer and BPH. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByLoeb S, Sanda M, Broyles D, Shin S, Bangma C, Wei J, Partin A, Klee G, Slawin K, Marks L, van Schaik R, Chan D, Sokoll L, Cruz A, Mizrahi I and Catalona W (2018) The Prostate Health Index Selectively Identifies Clinically Significant Prostate CancerJournal of Urology, VOL. 193, NO. 4, (1163-1169), Online publication date: 1-Apr-2015.Tekin A, Yuksel A, Tekin S, Gumrukcu G, Aslan A and Sengor F (2018) Post-Prostatic Massage Examination for Prediction of Asymptomatic Prostatitis in Needle Biopsies: A Prospective StudyJournal of Urology, VOL. 182, NO. 2, (564-569), Online publication date: 1-Aug-2009.KARAZANASHVILI G and ABRAHAMSSON P (2018) Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate CancerJournal of Urology, VOL. 169, NO. 2, (445-457), Online publication date: 1-Feb-2003.Horinaga M, Nakashima J, Ishibashi M, Oya M, Ohigashi T, Marumo K and Murai M (2018) Clinical Value of Prostate Specific Antigen Based Parameters for the Detection of Prostate Cancer on Repeat Biopsy: The Usefulness of Complexed Prostate Specific Antigen Adjusted for Transition Zone VolumeJournal of Urology, VOL. 168, NO. 3, (986-990), Online publication date: 1-Sep-2002.RECKER F, KWIATKOWSKI M, HUBER A, STAMM B, LEHMANN K and TSCHOLL R (2018) PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCEJournal of Urology, VOL. 166, NO. 3, (851-855), Online publication date: 1-Sep-2001.FINNE P, ZHANG W, AUVINEN A, LEINONEN J, MÄÄTTÄNEN L, RANNIKKO S, TAMMELA T and STENMAN U (2018) USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCERJournal of Urology, VOL. 164, NO. 6, (1956-1960), Online publication date: 1-Dec-2000.FOWLER J, SANDERS J, BIGLER S, RIGDON J, KILAMBI N and LAND S (2018) PERCENT FREE PROSTATE SPECIFIC ANTIGEN AND CANCER DETECTION IN BLACK AND WHITE MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN 2.5 TO 9.9 NG./ML.Journal of Urology, VOL. 163, NO. 5, (1467-1470), Online publication date: 1-May-2000.ROBERTS R, BERGSTRALH E, PETERSON N, BOSTWICK D, LIEBER M and JACOBSEN S (2018) POSITIVE AND NEGATIVE BIOPSIES IN THE PRE-PROSTATE SPECIFIC ANTIGEN AND PROSTATE SPECIFIC ANTIGEN ERAS, 1980 TO 1997Journal of Urology, VOL. 163, NO. 5, (1471-1475), Online publication date: 1-May-2000.BRAWER M, CHELI C, NEAMAN I, GOLDBLATT J, SMITH C, SCHWARTZ M, BRUZEK D, MORRIS D, SOKOLL L, CHAN D, YEUNG K, PARTIN A and ALLARD W (2018) COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCERJournal of Urology, VOL. 163, NO. 5, (1476-1480), Online publication date: 1-May-2000.HAESE A, BECKER C, NOLDUS J, GRAEFEN M, HULAND E, HULAND H and LILJA H (2018) HUMAN GLANDULAR KALLIKREIN 2: A POTENTIAL SERUM MARKER FOR PREDICTING THE ORGAN CONFINED VERSUS NONORGAN CONFINED GROWTH OF PROSTATE CANCERJournal of Urology, VOL. 163, NO. 5, (1491-1497), Online publication date: 1-May-2000.BECKER C, PIIRONEN T, PETTERSSON K, BJöRK T, WOJNO K, OESTERLING J and LILJA H (2018) DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUMJournal of Urology, VOL. 163, NO. 1, (311-316), Online publication date: 1-Jan-2000.BERRUTI A, DOGLIOTTI L, FASOLIS G, MOSCA A, TARABUZZI R, TORTA M, MARI M, FONTANA D and ANGELI A (2018) CHANGES IN FREE AND FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN AFTER ANDROGEN DEPRIVATION OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCERJournal of Urology, VOL. 161, NO. 1, (176-181), Online publication date: 1-Jan-1999.CLEMENTS J, ROHDE P, ALLEN V, HYLAND V, SAMARATUNGA M, TILLEY W, LAVIN M and GARDINER R (2018) MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCERJournal of Urology, VOL. 161, NO. 4, (1337-1343), Online publication date: 1-Apr-1999. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 162, NO. 6, (2034-2035), Online publication date: 1-Dec-1999.SOUTHWICK P, CATALONA W, PARTIN A, SLAWIN K, BRAWER M, FLANIGAN R, PATEL A, RICHIE J, WALSH P, SCARDINO P, LANGE P, GASIOR G, PARSON R and LOVELAND K (2018) PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIALJournal of Urology, VOL. 162, NO. 4, (1346-1351), Online publication date: 1-Oct-1999.POLASCIK T, OESTERLING J and PARTIN A (2018) PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOINGJournal of Urology, VOL. 162, NO. 2, (293-306), Online publication date: 1-Aug-1999.JUNG K, MEYER A, LEIN M, RUDOLPH B, SCHNORR D and LOENING S (2018) RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN IN SERUM CANNOT DISTINGUISH PATIENTS WITH PROSTATE CANCER FROM THOSE WITH CHRONIC INFLAMMATION OF THE PROSTATEJournal of Urology, VOL. 159, NO. 5, (1595-1598), Online publication date: 1-May-1998.Woodrum D, Brawer M, Partin A, Catalona W and Southwick P (2018) INTERPRETATION OF FREE PROSTATE SPECIFIC ANTIGEN CLINICAL RESEARCH STUDIES FOR THE DETECTION OF PROSTATE CANCERJournal of Urology, VOL. 159, NO. 1, (5-12), Online publication date: 1-Jan-1998.ESPANA F, ROYO M, MARTINEZ M, ENGUIDANOS M, VERA C, ESTELLES A, AZNAR J, JIMENEZ-CRUZ J and HEEB M (2018) FREE AND COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIFFERENTIATION OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER: STUDIES IN SERUM AND PLASMA SAMPLESJournal of Urology, VOL. 160, NO. 6 Part 1, (2081-2088), Online publication date: 1-Dec-1998.NIEMCZYK P, CUMMINGS K, SARVAZYAN A, BANCILA E, WARD W and WEISS R (2018) CORRELATION OF MECHANICAL IMAGING AND HISTOPATHOLOGY OF RADICAL PROSTATECTOMY SPECIMENS: A PILOT STUDY FOR DETECTING PROSTATE CANCERJournal of Urology, VOL. 160, NO. 3 Part 1, (797-801), Online publication date: 1-Sep-1998.CHEN Z, CHEN H and STAMEY T (2018) MONOCLONAL ANTIBODIES 2F5 AND 4G10 AGAINST PROSTATE SPECIFIC ANTIGEN (PSA) COMPLEXED TO alpha 1-ANTICHYMOTRYPSINJournal of Urology, VOL. 160, NO. 3 Part 1, (870-875), Online publication date: 1-Sep-1998.NOLDUS J, GRAEFEN M, HULAND E, BUSCH C, HAMMERER P and HULAND H (2018) THE VALUE OF THE RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN FOR STAGING PURPOSES IN PREVIOUSLY UNTREATED PROSTATE CANCERJournal of Urology, VOL. 159, NO. 6, (2004-2008), Online publication date: 1-Jun-1998.ORNSTEIN D, SMITH D, HUMPHREY P and CATALONA W (2018) THE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCERJournal of Urology, VOL. 159, NO. 4, (1234-1237), Online publication date: 1-Apr-1998.Pannek J, Marks L, Pearson J, Rittenhouse H, Chan D, Shery E, Gormley G, Subong E, Kelley C, Stoner E and Partin A (2018) INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 159, NO. 2, (449-453), Online publication date: 1-Feb-1998.PAUS E, NILSSON O, BORMER O, FOSSA S, OTNES B and SKOVLUND E (2018) STABILITY OF FREE AND TOTAL PROSTATE SPECIFIC ANTIGEN IN SERUM FROM PATIENTS WITH PROSTATE CARCINOMA AND BENIGN HYPERPLASIAJournal of Urology, VOL. 159, NO. 5, (1599-1605), Online publication date: 1-May-1998.Noldus J, Chen Z and Stamey T (2018) ISOLATION AND CHARACTERIZATION OF FREE FORM PROSTATE SPECIFIC ANTIGEN (f-PSA) IN SERA OF MEN WITH PROSTATE CANCERJournal of Urology, VOL. 158, NO. 4, (1606-1609), Online publication date: 1-Oct-1997.O'Dowd G, Veltri R, Orozco R, Miller M and Oesterling J (2018) Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate CancerJournal of Urology, VOL. 158, NO. 3, (687-698), Online publication date: 1-Sep-1997.Ornstein D, Rao G, Smith D, Ratliff T, Basler J and Catalona W (2018) Effect of Digital Rectal Examination and Needle Biopsy on Serum Total and Percentage of Free Prostate Specific Antigen LevelsJournal of Urology, VOL. 157, NO. 1, (195-198), Online publication date: 1-Jan-1997.Irani J, Millet C, Levillain P, Dore B, Begon F and Aubert J (2018) Serum-to-Urinary Prostate Specific Antigen Ratio: Its Impact in Distinguishing Prostate Cancer When Serum Prostate Specific Antigen Level is 4 to 10 ng./ml.Journal of Urology, VOL. 157, NO. 1, (185-188), Online publication date: 1-Jan-1997.Haese A, Graefen M, Noldus J, Hammerer P, Huland E and Huland H (2018) PROSTATIC VOLUME AND RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN IN PATIENTS WITH PROSTATIC CANCER OR BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 158, NO. 6, (2188-2192), Online publication date: 1-Dec-1997.Chen Z, Chen H and Stamey T (2018) Prostate Specific Antigen in Benign Prostatic Hyperplasia: Purification and CharacterizationJournal of Urology, VOL. 157, NO. 6, (2166-2170), Online publication date: 1-Jun-1997.Nixon R, Wener M, Smith K, Parson R, Strobel S and Brawer M (2018) Biological Variation of Prostate Specific Antigen Levels In Serum: An Evaluation of Day-to-Day Physiological Fluctuations in a Well-Defined Cohort of 24 PatientsJournal of Urology, VOL. 157, NO. 6, (2183-2190), Online publication date: 1-Jun-1997.Collins G, Martin P, Wynn-Davies A, Brooman P and O'Reilly P (2018) The effect of Digital Rectal Examination, Flexible Cystoscopy and Prostatic Biopsy on Free and Total Prostate Specific Antigen, and the Free-to-Total Prostate Specific Antigen Ratio in Clinical PracticeJournal of Urology, VOL. 157, NO. 5, (1744-1747), Online publication date: 1-May-1997.Bangma C, Kranse R, Blijenberg B and Schroder F (2018) The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate CarcinomaJournal of Urology, VOL. 157, NO. 2, (544-547), Online publication date: 1-Feb-1997.Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, Kato M, Sugisaki H and Tomaru T (2018) Significance of Serum Free Prostate Specific Antigen in the Screening of Prostate CancerJournal of Urology, VOL. 156, NO. 6, (1964-1968), Online publication date: 1-Dec-1996.Chen Z, Komatsu K, Prestigiacomo A and Stamey T (2018) Addition of Purified Prostate Specific Antigen to Serum from Female Subjects: Studies on the Relative Inhibition by alpha 2-Macroglobulin and alpha 1-AntichymotrypsinJournal of Urology, VOL. 156, NO. 4, (1357-1363), Online publication date: 1-Oct-1996.Elgamal A, Cornillie F, Van Poppel H, Van de Voorde W, McCabe R and Baert L (2018) Free-to-Total Prostate Specific Antigen Ratio as a Single Test for Detection of Significant Stage T1c Prostate CancerJournal of Urology, VOL. 156, NO. 3, (1042-1049), Online publication date: 1-Sep-1996.Prestigiacomo A, Lilja H, Pettersson K, Wolfert R and Stamey T (2018) A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenarioJournal of Urology, VOL. 156, NO. 2, (350-354), Online publication date: 1-Aug-1996.Oesterling J, Jacobsen S, Klee G, Petterson K, Piironen T, Abrahamsson P, Stenman U, Dowell B, Lovgren T and Lilja H (2018) Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and RatiosJournal of Urology, VOL. 154, NO. 3, (1090-1095), Online publication date: 1-Sep-1995.Tibblin G, Welin L, Bergstrom R, Ronquist G, Norlen B and Adami H (2018) Value of Prostate Specific Antigen in Early Diagnosis of Prostate Cancer: Study of Men Born in 1913Journal of Urology, VOL. 154, NO. 4, (1386-1389), Online publication date: 1-Oct-1995.Kim E, Smith N and Grayhack J (2018) Prostate Specific Antigen in the Expressed Prostatic Fluid of Men with Benign Prostatic Hyperplasia and Prostate CarcinomaJournal of Urology, VOL. 154, NO. 5, (1802-1805), Online publication date: 1-Nov-1995.Lange P (2018) Future studies in localized prostate cancer. What should we think? What can we do?Journal of Urology, VOL. 152, NO. 5 Part 2, (1932-1938), Online publication date: 1-Nov-1994.Partin A and Oesterling J (2018) The Clinical Usefulness of Prostate Specific Antigen: Update 1994Journal of Urology, VOL. 152, NO. 5 Part 1, (1358-1368), Online publication date: 1-Nov-1994.Stamey T, Chen Z and Prestigiacomo A (2018) Serum Prostate Specific Antigen Binding α1-Antichymotrypsin: Influence of Cancer Volume, Location and Therapeutic Selection of Resistant ClonesJournal of Urology, VOL. 152, NO. 5 Part 1, (1510-1514), Online publication date: 1-Nov-1994.Monda J, Barry M and Oesterling J (2018) Prostate Specific Antigen Cannot Distinguish Stage T1a (A1) Prostate Cancer from Benign Prostatic HyperplasiaJournal of Urology, VOL. 151, NO. 5, (1291-1295), Online publication date: 1-May-1994. Volume 150Issue 1July 1993Page: 100-105 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsprostatic hypertrophyantigens, neoplasmalpha 1-antichymotrypsinprostatic neoplasmsMetricsAuthor Information Anders christensson More articles by this author Thomas Björk More articles by this author Olle Nilsson More articles by this author Ulrika Dahlén More articles by this author Marja-Terttu Matikainen More articles by this author Abraham T.K. Cockett More articles by this author Per-Anders Abrahamsson More articles by this author Hans Lilja More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W1847856759 created "2016-06-24" @default.
• W1847856759 creator A5002541798 @default.
• W1847856759 creator A5020495334 @default.
• W1847856759 creator A5043570965 @default.
• W1847856759 creator A5051114608 @default.
• W1847856759 creator A5056770711 @default.
• W1847856759 creator A5067152237 @default.
• W1847856759 creator A5081019093 @default.
• W1847856759 creator A5088354027 @default.
• W1847856759 date "1993-07-01" @default.
• W1847856759 modified "2023-10-16" @default.
• W1847856759 title "Serum Prostate Specific Antigen Complexed to<i>α</i>1-Antichymotrypsin as an Indicator of Prostate Cancer" @default.
• W1847856759 cites W1576487122 @default.
• W1847856759 cites W1583346750 @default.
• W1847856759 cites W1845134010 @default.
• W1847856759 cites W1963764466 @default.
• W1847856759 cites W1970218306 @default.
• W1847856759 cites W1985438891 @default.
• W1847856759 cites W1986028457 @default.
• W1847856759 cites W1987207937 @default.
• W1847856759 cites W1991700287 @default.
• W1847856759 cites W1997492763 @default.
• W1847856759 cites W2001423599 @default.
• W1847856759 cites W2019490921 @default.
• W1847856759 cites W2027925208 @default.
• W1847856759 cites W2033556591 @default.
• W1847856759 cites W2034239274 @default.
• W1847856759 cites W2061734101 @default.
• W1847856759 cites W2330292521 @default.
• W1847856759 cites W2335679869 @default.
• W1847856759 cites W3221563 @default.
• W1847856759 cites W333212257 @default.
• W1847856759 cites W38427941 @default.
• W1847856759 cites W4254658040 @default.
• W1847856759 cites W53877061 @default.
• W1847856759 doi "https://doi.org/10.1016/s0022-5347(17)35408-3" @default.
• W1847856759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7685416" @default.
• W1847856759 hasPublicationYear "1993" @default.
• W1847856759 type Work @default.
• W1847856759 sameAs 1847856759 @default.
• W1847856759 citedByCount "633" @default.
• W1847856759 countsByYear W18478567592012 @default.
• W1847856759 countsByYear W18478567592013 @default.
• W1847856759 countsByYear W18478567592014 @default.
• W1847856759 countsByYear W18478567592015 @default.
• W1847856759 countsByYear W18478567592016 @default.
• W1847856759 countsByYear W18478567592017 @default.
• W1847856759 countsByYear W18478567592018 @default.
• W1847856759 countsByYear W18478567592019 @default.
• W1847856759 countsByYear W18478567592020 @default.
• W1847856759 countsByYear W18478567592021 @default.
• W1847856759 countsByYear W18478567592022 @default.
• W1847856759 countsByYear W18478567592023 @default.
• W1847856759 crossrefType "journal-article" @default.
• W1847856759 hasAuthorship W1847856759A5002541798 @default.
• W1847856759 hasAuthorship W1847856759A5020495334 @default.
• W1847856759 hasAuthorship W1847856759A5043570965 @default.
• W1847856759 hasAuthorship W1847856759A5051114608 @default.
• W1847856759 hasAuthorship W1847856759A5056770711 @default.
• W1847856759 hasAuthorship W1847856759A5067152237 @default.
• W1847856759 hasAuthorship W1847856759A5081019093 @default.
• W1847856759 hasAuthorship W1847856759A5088354027 @default.
• W1847856759 hasConcept C121608353 @default.
• W1847856759 hasConcept C126322002 @default.
• W1847856759 hasConcept C126894567 @default.
• W1847856759 hasConcept C143998085 @default.
• W1847856759 hasConcept C147483822 @default.
• W1847856759 hasConcept C203014093 @default.
• W1847856759 hasConcept C20417620 @default.
• W1847856759 hasConcept C2776235491 @default.
• W1847856759 hasConcept C2780192828 @default.
• W1847856759 hasConcept C2781406297 @default.
• W1847856759 hasConcept C71924100 @default.
• W1847856759 hasConceptScore W1847856759C121608353 @default.
• W1847856759 hasConceptScore W1847856759C126322002 @default.
• W1847856759 hasConceptScore W1847856759C126894567 @default.
• W1847856759 hasConceptScore W1847856759C143998085 @default.
• W1847856759 hasConceptScore W1847856759C147483822 @default.
• W1847856759 hasConceptScore W1847856759C203014093 @default.
• W1847856759 hasConceptScore W1847856759C20417620 @default.
• W1847856759 hasConceptScore W1847856759C2776235491 @default.
• W1847856759 hasConceptScore W1847856759C2780192828 @default.
• W1847856759 hasConceptScore W1847856759C2781406297 @default.
• W1847856759 hasConceptScore W1847856759C71924100 @default.
• W1847856759 hasIssue "1" @default.
• W1847856759 hasLocation W18478567591 @default.
• W1847856759 hasLocation W18478567592 @default.
• W1847856759 hasOpenAccess W1847856759 @default.
• W1847856759 hasPrimaryLocation W18478567591 @default.
• W1847856759 hasRelatedWork W1992657261 @default.
• W1847856759 hasRelatedWork W2038565121 @default.
• W1847856759 hasRelatedWork W2148869351 @default.
• W1847856759 hasRelatedWork W2372081072 @default.
• W1847856759 hasRelatedWork W2373651588 @default.
• W1847856759 hasRelatedWork W2897445903 @default.
• W1847856759 hasRelatedWork W2944341298 @default.
• W1847856759 hasRelatedWork W3129209394 @default.

• next